Biocryst Pharmaceuticals (BCRX) Receivables - Net (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) reported Receivables - Net of $110.76 million for Q2 2026, up 21.5% from $91.18 million a year earlier and up 1.4% from the prior quarter.
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Receivables - Net (2010 - 2026) Analysis & Trends
At the end of FY2025, Biocryst Pharmaceuticals posted Receivables - Net of $106.82 million, up 35.1% from FY2024.
- Receivables - Net has increased for five consecutive years, with a five-year compound annual growth rate of 65.3% (FY2020 to FY2025).
- By year, Receivables - Net came in at $79.07 million in FY2024 (+38.8%), $56.95 million in FY2023 (+12.6%), $50.6 million in FY2022 (+72.0%) and $29.41 million in FY2021 (+240.2%).
- The Q2 2026 figure ranks as the highest quarterly Receivables - Net in data going back to Q4 2010.
- Year over year, Receivables - Net has now increased in each of the last 20 quarters, with growth averaging 33.4% over the last eight quarters.
- Over the past five years, the year-over-year growth in Receivables - Net ranged from 17.0% (Q1 2026) to 383.4% (Q3 2021).
- Per Business Quant data, the three quarters before Q2 2026 came in at $109.27 million (Q1 2026), $106.82 million (Q4 2025) and $91.33 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn |
| 10 | Biocryst Pharmaceuticals | 2.16 Bn | 1.08 Bn | 214.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 110.76 Mn |
| Mar 31, 2026 | 109.27 Mn |
| Dec 31, 2025 | 106.82 Mn |
| Sep 30, 2025 | 91.33 Mn |
| Jun 30, 2025 | 91.18 Mn |
| Mar 31, 2025 | 93.39 Mn |
| Dec 31, 2024 | 76.28 Mn |
| Sep 30, 2024 | 72.46 Mn |
| Jun 30, 2024 | 68.76 Mn |
| Mar 31, 2024 | 60.59 Mn |
| Dec 31, 2023 | 54.15 Mn |
| Sep 30, 2023 | 53.65 Mn |
| Jun 30, 2023 | 57.67 Mn |
| Mar 31, 2023 | 48.64 Mn |
| Dec 31, 2022 | 41.51 Mn |
| Sep 30, 2022 | 42.61 Mn |
| Jun 30, 2022 | 41.49 Mn |
| Mar 31, 2022 | 36.42 Mn |
| Dec 31, 2021 | 27.38 Mn |
| Sep 30, 2021 | 26.21 Mn |
API Access
Biocryst Pharmaceuticals Receivables - Net API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables-net&ticker=BCRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables-net", "ticker": "BCRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables-net&ticker=BCRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();